FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080326435> ?p ?o ?g. }

• W2080326435 endingPage "553" @default.
• W2080326435 startingPage "553" @default.
• W2080326435 abstract "Editorials1 October 1983Labetalol: An Alpha- and Beta-Adrenoceptor Blocking DrugERIC L. MICHELSON, M.D., WILLIAM H. FRISHMAN, M.D.ERIC L. MICHELSON, M.D.Search for more papers by this author, WILLIAM H. FRISHMAN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-99-4-553 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptBeta-adrenoceptor blockers are established drugs for the primary and adjunctive treatment of various cardiovascular disorders. These agents are useful in the management of patients with systemic hypertension, angina pectoris, hypertrophic cardiomyopathy, and a spectrum of cardiac dysrhythmias. Several beta-blockers have also shown cardioprotective effects in patients surviving a recent myocardial infarction, by reducing the incidence of death, sudden death, and reinfarction (1). Apparently, the major mechanism by which beta-blockers mediate their potent cardiovascular actions is via the competitive blockade of beta-1 adrenergic receptors that predominate in the heart. This hypothesis is not to discount the accumulating evidence of the additional...References1. MAYEBERLEINFURBERGPASSAMANIDEMETS GKCED. Secondary prevention after myocardial infarction: a review of long-term trials. Prog Cardiovasc Dis. 1982;24:331-59. CrossrefMedlineGoogle Scholar2. FRISHMAN W. Clinical Pharmacology of the Beta-Adrenoceptor Blocking Drugs. New York: Appleton-Century Crofts, 1980. Google Scholar3. RICHARDS D. Pharmacological effects of labetalol in man. Br J Clin Pharmacol. 1976;3 (suppl 3):721-3. MedlineGoogle Scholar4. MEHTACOHN JJ. Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects. Circulation. 1977;55:370-5. CrossrefMedlineGoogle Scholar5. FRISHMANHALPRIN WS. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 7. New horizons in beta-adrenoceptor blockade therapy: labetalol. Am Heart J. 1979;98:660-5. CrossrefMedlineGoogle Scholar6. BRITTAINHARRISJACKRICHARDS RDDD. Labetalol. In: GOLDBERG ME, ed., Pharmacological and Biochemical Properties of Drug Substances. Washington, DC: American Pharmaceutical Association; 1979;229-54. Google Scholar7. DAGEHSIEH RC. Direct vasodilatation by labetalol in anaesthetized dogs. Br J Pharmacol. 1980;70:287-93. CrossrefMedlineGoogle Scholar8. PRICHARDRICHARDS BD. Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium. Br J Clin Pharmacol. 1979;8 (suppl 2):239S-44S. CrossrefGoogle Scholar9. CAREYWHALLEY BE. Labetalol possesses beta-adrenoceptor agonist action on the rat isolated uterus. J Pharm Pharmacol. 1979;31:791-2. CrossrefMedlineGoogle Scholar10. LEVYRICHARDS GD. Labetalol. In: SCRIABINE A, ed. Pharmacology of Antihypertensive Drugs. New York; Raven Press: 1980;325-47. Google Scholar11. PRICHARDRICHARDS BD. Comparison of labetalol with other antihypertensive drugs. Br J Clin Pharmacol. 1982;13 (suppl 1):41S-7S. CrossrefMedlineGoogle Scholar12. BRITTAINDREWLEVY RGG. The α- and β- adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anaesthetized dogs and in isolated tissues. Br J Pharmacol. 1982;77:105-14. CrossrefMedlineGoogle Scholar13. BAUMSYBERTZ TE. Antihypertensive actions of an isomer of labetalol and other vasodilator-β-adrenoceptor blockers. Fed Proc. 1983;42:176-81. MedlineGoogle Scholar14. LOUISCHRISTOPHIDISBRIGNELLVIJAYASEKARANMCNEILVAJDA WNMVJF. Labetalol: bioavailability, drug plasma levels, plasma renin and catecholamines in acute and chronic treatment of resistant hypertension. Aust NZ J Med. 1978;8:602-9. CrossrefMedlineGoogle Scholar15. BROGDENHEELSPEIGHTAVERY RRTG. Labetalol: a review of its pharmacology and therapeutic uses in hypertension. Drugs. 1978;15:251-70. CrossrefMedlineGoogle Scholar16. MARTINHOPKINSBLAND LRR. Metabolism of labetalol by animals and man. Br J Clin Pharmacol. 1976;3(suppl 3):695-710. MedlineGoogle Scholar17. REIDMEREDITHELLIOTT JPH. Labetalol and the management of hypertension. J Cardiovasc Pharmacol. 1981;3 (suppl 1):S60-8. CrossrefMedlineGoogle Scholar18. MCNEILANDERSONLOUISMORGAN JAWD. Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects. Br J Clin Pharmacol. 1979;8(suppl 2):157S-61S. CrossrefGoogle Scholar19. HOMEIDAJACKSONROBERTS MLC. Decreased first-pass metabolism of labetalol in chronic liver disease. Br Med J. 1978;2:1048-50. CrossrefMedlineGoogle Scholar20. DARGIEDOLLERYDANIEL HCJ. Labetalol in resistant hypertension. Br J Clin Pharmacol. 1976;3(suppl 3):751-5. MedlineGoogle Scholar21. PUGSLEYARMSTRONGNASSIMBEILIN DBML. Controlled comparison of labetalol and propranolol in the management of severe hypertension. Br J Clin Pharmacol. 1976;3(suppl 3):777-82. MedlineGoogle Scholar22. ROSEIBROWNLEVERROBERTSONROBERTSONTRUST EJAAJP. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol. Br J Clin Pharmacol. 1976;3(suppl 3):809S-15S. MedlineGoogle Scholar23. LAMMINGSYMONDS GE. Use of labetalol and methyldopa in pregnancy-induced hypertension. Br J Clin Pharmacol. 1979;8:217S-22S. CrossrefGoogle Scholar24. MICHAEL C. Use of labetalol in the treatment of severe hypertension during pregnancy. Br J Clin Pharmacol. 1979;8(suppl 2):211S-5S. CrossrefGoogle Scholar25. MICHAEL C. The evaluation of labetalol in the treatment of hypertension complicating pregnancy. Br J Clin Pharmacol. 1982;13(suppl 1):127S-31S. CrossrefMedlineGoogle Scholar26. PRICHARDBOAKES BA. Labetalol in long-term treatment of hypertension. Br J Clin Pharmacol. 1976;3(suppl 3):743-50. MedlineGoogle Scholar27. A multicentre study of labetalol in hypertension. New Zealand Hypertension Study Group. NZ Med J. 1981;93:215-8. MedlineGoogle Scholar28. STERNTEICHERROSENTHAL NAT. The treatment of hypertension by labetalol—a new alpha- and beta-adrenoceptor blocking agent. Clin Cardiol. 1982;5;125-30. CrossrefMedlineGoogle Scholar29. PAPADEMETRIOUNOTARGIACOMOKHATRIFREIS VAIE. Treatment of severe hypertension with intravenous labetalol. Clin Pharmacol Ther. 1982;32:431-5. CrossrefMedlineGoogle Scholar30. WALLINO'NEILL JW. Labetalol: current research and therapeutic status. Arch Intern Med. 1983;143:485-90. CrossrefMedlineGoogle Scholar31. HUNTER J. Synergism between halothane and labetalol. Anesthesia. 1979;34:257-9. CrossrefMedlineGoogle Scholar32. MICHELSONLANGFORDFREIS EHE. Clinical Synopsis—Labetalol: The Effects of Acute Intravenous and Subsequent Oral Labetalol Treatment in Hypertensive Patients Requiring Urgent Blood Pressure Reduction (C81-009). Bloomfield, New Jersey; Schering Corporation: 1982;1-31. Google Scholar33. MAXWELL G. The effects of alpha- and beta-adrenoceptor antagonist (AH 5158) upon the general and coronary hemodynamics of intact dogs. Br J Pharmacol. 1973;49:370-2. CrossrefMedlineGoogle Scholar34. LUND-JOHANSENBAKKE PO. Haemodynamic effects and plasma concentrations of labetalol during long-term treatment of essential hypertension. Br J Clin Pharmacol. 1979;7:169-74. CrossrefMedlineGoogle Scholar35. TAYLORSILKENELSONOKOLIAHUJA SBGRR. Haemodynamic advantages of combined alpha-blockade and beta-blockade over beta-blockade alone in patients with coronary heart disease. Br Med J. 1982;285:325-7. CrossrefMedlineGoogle Scholar36. KOCH G. Hemodynamic changes after acute and long-term combined alpha-beta-adrenoceptor blockade with labetalol as compared with beta-receptor blockade. J Cardiovasc Pharmacol. 1981;3(suppl 1):S30-41. CrossrefMedlineGoogle Scholar37. GAGNONMORISSETTEPRESANTSAVARDLEMIRE RMSDJ. Hemodynamic and coronary effects of intravenous labetalol in coronary artery disease. Am J Cardiol. 1982;49:1267-9. CrossrefMedlineGoogle Scholar38. FRISHMANSTROMKIRSCHNER WJM. Labetalol therapy in patients with systemic hypertension and angina pectoris: effects of combined alpha- and beta-adrenoreceptor blockade. Am J Cardiol. 1981;48:917-28. CrossrefMedlineGoogle Scholar39. SPECIAL REPORT TO THE BRITISH COMMITTEE ON SAFETY OF MEDICINES. Incidence of Side Effects Associated with Labetalol. British Monitored Release Trials of 6,638 Patients. British Committee on Safety of Medicines; 1978. Google Scholar40. TAKEDAKANEKOOMAE TYT. The use of labetalol in Japan: results of multicentre clinical trials. Br J Clin Pharmacol. 1982;13 (suppl 1):49S-57S. CrossrefMedlineGoogle Scholar41. WAAL-MANNINGSIMPSON HF. Review of long-term treatment with labetalol. Br J Clin Pharmacol. 1982;13(suppl 1):65S-73S. CrossrefMedlineGoogle Scholar42. MICHELSONFRISHMANSAWINSABOLLONGPOLAND EWHSCM. Long-term efficacy and safety of labetalol in the treatment of hypertension [Abstract]. J Am Coll Cardiol. 1983;1:611. Google Scholar43. GEORGEMANOCHABURFORDCONRADKINASEWITZ RKJSG. Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease. Chest. 1983;3:457-60. CrossrefGoogle Scholar44. RASMUSSENNIELSEN SP. Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension Br J Clin Pharmacol. 1981;12:349-53. CrossrefMedlineGoogle Scholar45. LARSENPEDERSEN JE. Comparison of the effects of propranolol and labetalol on renal haemodynamics at rest and during exercise in essential hypertension. Eur J Clin Pharmacol. 1980;18:135-9. CrossrefMedlineGoogle Scholar46. FRISHMANMICHELSONJOHNSON WEB. Effects of beta-adrenergic blockade on plasma lipids: a double-blind randomized placebocontrolled multi-center comparison of labetalol and metoprolol in patients with hypertension [Abstract]. Am J Cardiol. 1982;49:984. CrossrefGoogle Scholar47. KANE J. Labetalol in general practice: a review. Br J Clin Pharmacol. 1982;13(suppl 1):59S-63S. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Albert Einstein College of Medicine Bronx, New York PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByHepatotoxicity of Cardiovascular and Antidiabetic DrugsWilliam Howard Frishman, MD: A Conversation With the EditorLabetalol HepatotoxicityEric L. Michelson, MDLabetalol Compared with Propranolol in Patients with Both Angina Pectoris and Systemic Hypertension: A Double-Blind StudyEjaculatory Failure and Urinary Dysfunction Secondary to LabetalolEffect of labetalol on limb haemodynamics in patients following coronary artery bypass graft surgery.Pseudoephedrine-induced hypertensive emergency: Treatment with labetalolIn vitro effects of ethanolamine on insulin secretionThe Role of Stress and the Sympathetic Nervous System in Hypertension and Ischemic Heart Disease: Advantages of Therapy with β-Receptor BlockersLabetalol and Determinations of Pressor HormonesC. HARVENGT, M.D., PH.D. 1 October 1983Volume 99, Issue 4Page: 553-555KeywordsAnginaArrhythmiaCardiomyopathiesCardiovascular therapyDrugsHeartHypertensionMyocardial infarction Issue Published: 1 October 1983 PDF DownloadLoading ..." @default.
• W2080326435 created "2016-06-24" @default.
• W2080326435 creator A5020544805 @default.
• W2080326435 creator A5037002715 @default.
• W2080326435 date "1983-10-01" @default.
• W2080326435 modified "2023-10-16" @default.
• W2080326435 title "Labetalol: An Alpha- and Beta-Adrenoceptor Blocking Drug" @default.
• W2080326435 cites W1528181437 @default.
• W2080326435 cites W1553472638 @default.
• W2080326435 cites W1946286806 @default.
• W2080326435 cites W1961331818 @default.
• W2080326435 cites W1969744700 @default.
• W2080326435 cites W1974811187 @default.
• W2080326435 cites W1981770296 @default.
• W2080326435 cites W1991695353 @default.
• W2080326435 cites W2007307461 @default.
• W2080326435 cites W2016832716 @default.
• W2080326435 cites W2019049004 @default.
• W2080326435 cites W2021650509 @default.
• W2080326435 cites W2026005096 @default.
• W2080326435 cites W2029499719 @default.
• W2080326435 cites W2030421447 @default.
• W2080326435 cites W2031285087 @default.
• W2080326435 cites W2034887650 @default.
• W2080326435 cites W2041875735 @default.
• W2080326435 cites W2053698511 @default.
• W2080326435 cites W2063262042 @default.
• W2080326435 cites W2063601172 @default.
• W2080326435 cites W2069179177 @default.
• W2080326435 cites W2071310284 @default.
• W2080326435 cites W2075541661 @default.
• W2080326435 cites W2092859054 @default.
• W2080326435 cites W2094897544 @default.
• W2080326435 cites W2110702140 @default.
• W2080326435 cites W2157440460 @default.
• W2080326435 cites W2167496348 @default.
• W2080326435 cites W2399115342 @default.
• W2080326435 cites W2403300407 @default.
• W2080326435 cites W2409867706 @default.
• W2080326435 cites W2418278928 @default.
• W2080326435 cites W2468868375 @default.
• W2080326435 cites W53172285 @default.
• W2080326435 cites W87995391 @default.
• W2080326435 doi "https://doi.org/10.7326/0003-4819-99-4-553" @default.
• W2080326435 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6137987" @default.
• W2080326435 hasPublicationYear "1983" @default.
• W2080326435 type Work @default.
• W2080326435 sameAs 2080326435 @default.
• W2080326435 citedByCount "12" @default.
• W2080326435 countsByYear W20803264352013 @default.
• W2080326435 crossrefType "journal-article" @default.
• W2080326435 hasAuthorship W2080326435A5020544805 @default.
• W2080326435 hasAuthorship W2080326435A5037002715 @default.
• W2080326435 hasConcept C105795698 @default.
• W2080326435 hasConcept C126322002 @default.
• W2080326435 hasConcept C141071460 @default.
• W2080326435 hasConcept C144745244 @default.
• W2080326435 hasConcept C199360897 @default.
• W2080326435 hasConcept C2775944032 @default.
• W2080326435 hasConcept C2776174256 @default.
• W2080326435 hasConcept C2777962398 @default.
• W2080326435 hasConcept C2778151854 @default.
• W2080326435 hasConcept C2778198053 @default.
• W2080326435 hasConcept C2779670145 @default.
• W2080326435 hasConcept C2780035454 @default.
• W2080326435 hasConcept C2909341992 @default.
• W2080326435 hasConcept C33923547 @default.
• W2080326435 hasConcept C41008148 @default.
• W2080326435 hasConcept C42219234 @default.
• W2080326435 hasConcept C49453240 @default.
• W2080326435 hasConcept C64943373 @default.
• W2080326435 hasConcept C71924100 @default.
• W2080326435 hasConcept C84393581 @default.
• W2080326435 hasConcept C98274493 @default.
• W2080326435 hasConceptScore W2080326435C105795698 @default.
• W2080326435 hasConceptScore W2080326435C126322002 @default.
• W2080326435 hasConceptScore W2080326435C141071460 @default.
• W2080326435 hasConceptScore W2080326435C144745244 @default.
• W2080326435 hasConceptScore W2080326435C199360897 @default.
• W2080326435 hasConceptScore W2080326435C2775944032 @default.
• W2080326435 hasConceptScore W2080326435C2776174256 @default.
• W2080326435 hasConceptScore W2080326435C2777962398 @default.
• W2080326435 hasConceptScore W2080326435C2778151854 @default.
• W2080326435 hasConceptScore W2080326435C2778198053 @default.
• W2080326435 hasConceptScore W2080326435C2779670145 @default.
• W2080326435 hasConceptScore W2080326435C2780035454 @default.
• W2080326435 hasConceptScore W2080326435C2909341992 @default.
• W2080326435 hasConceptScore W2080326435C33923547 @default.
• W2080326435 hasConceptScore W2080326435C41008148 @default.
• W2080326435 hasConceptScore W2080326435C42219234 @default.
• W2080326435 hasConceptScore W2080326435C49453240 @default.
• W2080326435 hasConceptScore W2080326435C64943373 @default.
• W2080326435 hasConceptScore W2080326435C71924100 @default.
• W2080326435 hasConceptScore W2080326435C84393581 @default.
• W2080326435 hasConceptScore W2080326435C98274493 @default.
• W2080326435 hasIssue "4" @default.
• W2080326435 hasLocation W20803264351 @default.
• W2080326435 hasLocation W20803264352 @default.

• next